Meeting
2011 ASCO Annual Meeting
Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial.
Authors
Lowell Anthony
Ochsner Kenner Medical Center
Lowell Anthony , Marc Peeters , John Hainsworth , Eric Baudin , Dieter Hoersch , Judith Klimovsky , Karen Grouss , Valentine Jehl , Marianne Pavel , James Yao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Other GI Cancer
Clinical Trial Registration Number
NCT00412061
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4078)
Abstract #
4078
Poster Bd #
32D
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET).
First Author: James C. Yao
Poster
2011 ASCO Annual Meeting
Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2.
First Author: James Yao
Poster
2011 ASCO Annual Meeting
Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors: Analysis by primary tumor site from RADIANT-2.
First Author: Edward Wolin
Poster
2011 ASCO Annual Meeting
Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial.
First Author: Manisha Shah